Moderna (NASDAQ: MRNA) made some big waves in late 2018, with its initial public offering (IPO) becoming the biggest ever for a biotech. The wave grew even larger this year as Moderna quickly emerged as a leader in the race to develop a coronavirus vaccine.
With the biotech stock gaining more than 250% so far this year, some investors might think that it's too late to jump aboard the Moderna bandwagon. But is Moderna still a smart stock to buy?
Image source: Getty Images.
Source Fool.com